ANDASPINALINJECTABLE
Approved
Apr 2019
Lifecycle
Post-LOE
Competitive Pressure
30/100
Data completeness
2/8 — Basic
BUPIVACAINE HYDROCHLORIDE (bupivacaine hydrochloride with dextrose) by B. Braun is impulses, presumably by increasing the threshold for electrical excitation in the nerve, by slowing the propagation of the nerve impulse, and by reducing the rate of rise of the action potential. First approved in 2019.
Drug data last refreshed Yesterday
Mechanism of Action
impulses, presumably by increasing the threshold for electrical excitation in the nerve, by slowing the propagation of the nerve impulse, and by reducing the rate of rise of the action potential. In general, the progression of anesthesia is related to the diameter, myelination, and conduction…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Company
B. Braun
Worked on BUPIVACAINE HYDROCHLORIDE at B. Braun? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.